Anlon Healthcare IPO opens on August 26: Check price band, financials and other key details

Anlon Healthcare is a chemical manufacturing company engaged in the manufacturing of pharma intermediates and active pharmaceutical ingredients (APIs). Its products serve as raw materials and key starting materials for manufacturing APIs and pharmaceutical formulations, including tablets, capsules, ointments, and syrups, as well as ingredients for nutraceuticals, personal care products, and animal health products.

Anlon Healthcare IPO details

Anlon Healthcare IPO aims to raise ₹121.03 crore through its public issue. The issue is a 100% fresh issue of over 1.33 crore shares.

The company has fixed the price band of the issue at ₹86 to ₹91 per share. The lot size, or the minimum bid quantity to apply for the issue, is 164 shares. This equates to a minimum investment amount of ₹14,924 per lot at the upper end of the price band for retail investors.

Anlon Healthcare has appointed Interactive Financial Services as the book-running lead managers of the IPO, while Kfin Technologies is the registrar for the issue.

Anlon Healthcare IPO: Important dates

Anlon Healthcare IPO will remain open for bidding from 26 to 29 August. After the bidding is closed, the allotment of shares is expected to be finalised on September 1.

Successful bidders can expect the shares to be credited to their demat accounts by September 2, with others receiving refunds on the same day. Anlon Healthcare shares are scheduled to list on the BSE and NSE on September 3.

Anlon Healthcare IPO objective

Financial snapshot:

About the company

The company operates from a single manufacturing facility located in Rajkot, Gujarat. The facility comprises two separate manufacturing blocks for pharmaceutical intermediates and APIs with an aggregate installed production capacity of 400 MTPA, along with four in-house laboratories and storage facilities.

The company’s product portfolio consists of 65 commercialised products, 28 products at the pilot stage, and 49 products at the laboratory testing/laboratory scale stage, totalling 142 products across various categories. This represents substantial growth from 83 total products in FY23 to 142 products in FY25. Its commercialised products include 22 pharmaceutical intermediates, 18 APIs, 20 nutraceutical APIs, 3 personal care products, and 2 animal health products. Key products span across therapeutic categories, including anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, and nutritional supplements.

The company has received Drug Master File (DMF) approvals from major regulatory authorities, including the Brazilian Health Regulatory Agency (ANVISA) for loxoprofen sodium dihydrate, the National Medical Products Administration of China (NMPA) for loxoprofen sodium dihydrate, and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) for loxoprofen sodium dihydrate and loxoprofen acid. It has filed 21 DMFs with regulatory authorities across the European Union, Russia, Japan, South Korea, Iran, Jordan, and Pakistan.

The company supplies products to both domestic and overseas markets, serving customers in over 15 countries. Their manufacturing facility has been audited and approved by 33 customers and their respective regulatory authorities. It manufactured and sold 338 MT of APIs and pharma intermediates in FY25 to 38 customers, compared to 153 MT to 39 customers in FY24 and 316 MT to 48 customers in FY23. Revenue concentration among the top 10 customers remains high at approximately 77-78% across the 3 fiscal years.

Anlon Healthcare IPO latest GMP

According to media reports and investorgain.com, the unlisted shares of Anlon Healthcare are currently trading flat with a grey market premium of 1-3% over the upper price band of ₹91.

Disclaimer: Grey Market Premium, or GMP, is an unofficial indicator of market sentiment toward an IPO. It is not regulated by the stock exchanges or SEBI. Upstox neither supports nor encourages grey market trading. Investors are advised to conduct their own research or consult an expert before making any investment decisions.